WO2016135470A1 - Chimeric protein - Google Patents

Chimeric protein Download PDF

Info

Publication number
WO2016135470A1
WO2016135470A1 PCT/GB2016/050451 GB2016050451W WO2016135470A1 WO 2016135470 A1 WO2016135470 A1 WO 2016135470A1 GB 2016050451 W GB2016050451 W GB 2016050451W WO 2016135470 A1 WO2016135470 A1 WO 2016135470A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
domain
caspase
cells
nucleic acid
Prior art date
Application number
PCT/GB2016/050451
Other languages
English (en)
French (fr)
Inventor
Martin PULÉ
Ryan TROWBRIDGE
Edward HODGKIN
Original Assignee
Ucl Business Plc
Syncona Partners Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2017542093A priority Critical patent/JP6836508B2/ja
Priority to KR1020177025985A priority patent/KR102601849B1/ko
Application filed by Ucl Business Plc, Syncona Partners Llp filed Critical Ucl Business Plc
Priority to CN202211656921.4A priority patent/CN116425882A/zh
Priority to EP16707195.0A priority patent/EP3197453B9/en
Priority to US15/526,097 priority patent/US10098911B2/en
Priority to AU2016225190A priority patent/AU2016225190B2/en
Priority to CA2973107A priority patent/CA2973107A1/en
Priority to EP22191585.3A priority patent/EP4147696A1/en
Priority to BR112017013689-9A priority patent/BR112017013689A2/pt
Priority to DK16707195.0T priority patent/DK3197453T3/da
Priority to KR1020237038544A priority patent/KR20230156817A/ko
Priority to PL16707195.0T priority patent/PL3197453T3/pl
Priority to MX2017007848A priority patent/MX2017007848A/es
Priority to CN201680006920.1A priority patent/CN107207621B/zh
Priority to SG11201705300VA priority patent/SG11201705300VA/en
Priority to RU2017132293A priority patent/RU2746755C2/ru
Priority to ES16707195T priority patent/ES2930623T3/es
Publication of WO2016135470A1 publication Critical patent/WO2016135470A1/en
Priority to IL252840A priority patent/IL252840B/en
Priority to ZA2017/04231A priority patent/ZA201704231B/en
Priority to US16/113,098 priority patent/US10478457B2/en
Priority to US16/598,652 priority patent/US11103532B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22062—Caspase-9 (3.4.22.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a chimeric protein useful in adoptive cell therapy (ACT).
  • the chimeric protein can act as a suicide gene enabling cells expressing the chimeric protein to be deleted.
  • the present invention also provides a nucleic acid encoding such a chimeric protein, a cell comprising such a nucleic acid and therapeutic uses thereof.
  • T-cell receptor transfer allows targeting of intracellular cancer antigens, while chimeric antigen receptors (CAR) allow targeting of surface cancer or lineage specific antigens.
  • CAR chimeric antigen receptors
  • graft-versus- host disease is a common and serious complication of DLI.
  • Administration of engineered T-cells has also resulted in toxicity.
  • on-target off-tumour toxicity has been reported in native T-cell receptor transfer studies against melanoma antigens; T-cells re-directed to the renal cell carcinoma antigen carbonic anhydrase IX (CAIX) produced unexpected hepatotoxicity.
  • Immune activation syndromes have been reported after CD19 CAR therapy.
  • vector-induced insertional mutagenesis results in a theoretical risk of lymphoproliferative disorders. The incidence and severity of these toxicities is unpredictable. Further, in contrast to a therapeutic protein or small molecules whose adverse events usually abate with the half-life of the therapeutic, T-cells engraft and replicate, potentially resulting in escalating and fulminant toxicity.
  • Suicide Genes in contrast to a therapeutic protein or small molecules whose adverse events usually abate with the half-life of the therapeutic, T
  • a suicide-gene is a genetically encoded mechanism which allows selective destruction of adoptively transferred cells, such as T-cells, in the face of unacceptable toxicity.
  • Two suicide-genes have been tested in clinical studies: Herpes Simplex Virus thymidine kinase (HSV-TK) and inducible caspase 9 (iCasp9).
  • HSV-TK Herpes Simplex Virus thymidine kinase
  • iCasp9 inducible caspase 9
  • HSV-TK herpes simplex virus l-derived thymidine kinase gene
  • EBV Epstein Barr virus
  • destruction of T cells causing graft-versus-host disease was incomplete, and the use of ganciclovir (or analogs) as a pro-drug to activate HSV-TK precludes administration of ganciclovir as an antiviral drug for cytomegalovirus infections.
  • HSV-TK-directed immune responses have resulted in elimination of HSV-TK-transduced cells, even in immunosuppressed human immunodeficiency virus and bone marrow transplant patients, compromising the persistence and hence efficacy of the infused T cells.
  • the activation mechanism behind Caspase 9 was exploited in the original iCasp9 molecule. All that is needed for Caspase 9 to become activated, is overcoming the energic barrier for Caspase 9 to homodimerize. The homodimer undergoes a conformational change and the proteolytic domain of one of a pair of dimers becomes active. Physiologically, this occurs by binding of the CARD domain of Caspase 9 to APAF-1. In iCasp9, the APAF-1 domain is replaced with a modified FKBP12 which has been mutated to selectively bind a chemical inducer of dimerization (CID). Presence of the CID results in homodimerization and activation.
  • CID chemical inducer of dimerization
  • iCasp9 is based on a modified human caspase 9 fused to a human FK506 binding protein (FKBP) (Straathof et al (2005) Blood 105:4247-4254). It enables conditional dimerization in the presence of a small molecule CID, known as AP1903.
  • AP1903 is an experimental drug and is considered biologically inert since it does not interact with wild-type FKBP12.
  • clinical experience with this agent is limited to a very small number of patients (Di Stasi, A. et al. (2011) N. Engl. J. Med. 365, 1673-1683; and luliucci, J. D. et al. (2001) J. Clin. Pharmacol.
  • executioner caspases can be activated by small molecules using a complex strategy which involves introduction of tobacco etch virus (TeV) proteolysis sites into Caspase 3 or 6 or 7 and co-expression with a split TEV protease which is recombined in the presence of rapamycin (Morgan et al (2014) Methods Enzymol. 544:179-213).
  • TeV tobacco etch virus
  • suicide genes have been proposed for instance full-length CD20 when expressed on a T-cell can render T-cells susceptible to lysis by the therapeutic anti- CD20 antibody Rituximab (Introna, M. et al. (2000) Hum. Gene Ther. 11 , 61 1-620). Further suicide genes have also been described on this theme of antibody recognition, for example: RQR8 renders T-cells susceptible to CD20 but is more compact than the full-length CD20 molecule (Philip, B. et al. (2014) Blood doi: 10.1182/blood-2014-01-545020); a truncated version of EGFR (huEGFRt) renders cells susceptible to lysis by anti-EGFR mAbs (Wang, X. et al.
  • FIG. 1 Cartoons showing different approaches to RapCasp9.
  • Double construct where two molecules are expressed separately. Each molecule has the catalytic domain of Casp9 fused with either FKBP12 or FRB respectively
  • Double construct where the catalytic domain of Caspase 9 is fused to FKBP12 and a separate small protein which is a fusion of two copies of FRB is co-expressed.
  • FIG. 2 Demonstration that it is possible to activate Caspase 9 with a heterodimerizer.
  • T-cells were either transduced with eGFP alone ( Figure 2a), or co- transduced with FKBP12-dCasp9 (co-expressing eGFP) and FRB-dCasp9 (co- expressing eBFP2) ( Figure 2b).
  • T-cells were intentionally only partially transduced so that the non-transduced T-cells would act as internal controls.
  • T-cells were then exposed to decreasing concentrations of Rapamycin. After 48 hours, cells were stained with Annexin-V and 7AAD and analysed by flow cytometry looking at the proportion of live cells which were expressing fluorescent proteins.
  • T-cells expressing both eGFP and eBFP2 were very effectively deleted even in the presence of the lowest concentration of Rapamycin.
  • FIG. 3 Function of RapCasp9 variants.
  • T-cells were transduced with (a) eGFP alone; (b) double transduced with FKBP12-Casp9 and FRB-Casp9 co-expressed with eGFP and eBFP2 respectively; (c) transduced with FRB-FKBP12-Casp9 and (d) transduced with FRB-Casp9-FKBP12 and (e) FBP12-Casp9-2A-FRB-FRBw. Only a proportion of cells were transduced, the negative cells acted as an internal negative control. T-cells were exposed for 48 hours to 2.5nM Rapamycin.
  • FIG. 4 Rapamycin and rapalogs.
  • Figure 6 Summary of gating strategy for Example 3.
  • Figures 7, 8 and 9 Study showing the killing of Jurkat cells transfected with the constructs shown in Figure 5 after incubation with various concentrations of rapamycin.
  • FIG. 11 Graph comparing Jurkat cell killing in the presence of rapamycin vs temsirolimus.
  • the present inventors have developed a new suicide gene, which dimerizes in the presence of a chemical inducer of dimerization (CID) such as rapamycin or a rapamycin analogue.
  • CID chemical inducer of dimerization
  • Rapamycin and rapamycin analogues induce heterodimerisation by generating an interface between the FRB domain of mTOR and FKBP12. This association results in FKBP12 blocking access to the mTOR active site inhibiting its function.
  • mTOR is a very large protein, the precise small segment of mTOR required for interaction with Rapamycin is known and can be used.
  • the present inventors have shown that it is possible to use the heterodimerization mediated by rapamycin to induce homodimerization of a caspase.
  • they have surprisingly shown that it is possible to create a multi-domain molecule, which includes (i) the FRB domain of mTOR; (ii) FKBP12; and (iii) a caspase, and use heterodimerization between the FRB domain of one copy of the molecule and the FKB12 domain of another copy of the molecule to cause homodimerization of the caspase domains.
  • the present invention provides a chimeric protein having the formula: Ht1-Ht2-Casp wherein
  • Casp is a caspase domain
  • Ht1 is a first heterodimerization domain
  • Ht2 is a second heterodimerization domain
  • the configuration is such that Ht1 does not heterodimerize to any significant extent with Ht2 within the same chimeric protein.
  • the caspase domain may comprise an initiator caspase selected from the following group: caspase-8, caspase-9 and caspase-10, or an executioner caspase selected from caspase-3 and caspase-7.
  • one heterodimerization domain may comprise an FK506-binding protein (FKBP) and the other heterodimerization domain may comprise an FRB domain of mTOR.
  • FKBP FK506-binding protein
  • a suitable CID is rapamycin or a rapamycin analog.
  • a chimeric protein which comprises a caspase domain and a heterodimerization domain which comprises an FK506-binding protein (FKBP12), and a chimeric protein which comprises a caspase domain and a heterodimerization domain which comprises an FRB domain of mTOR.
  • FKBP12 FK506-binding protein
  • Ht1-Casp and Ht2-Ht2 wherein Ht1-Casp is a chimeric protein comprising a caspase domain (Casp) and a first heterodimerization domain (Ht1); and Ht2-Ht2 is an interfacing protein comprising two or more second heterodimerization domains (Ht2); and
  • a pair of the chimeric proteins Ht1-Casp9 interact such that Ht1 from each chimeric protein heterodimerizes with an Ht2 domain from the interfacing protein, causing homodimerization of the two caspase domains.
  • Casp is a caspase domain
  • Ht1 is a first heterodimerization domain
  • Ht2 is a second heterodimerization domain
  • one heterodimerization domain comprises an FK506-binding protein (FKBP) and the other heterodimerization domain comprises an FRB domain of mTOR and the CID is rapamycin or a derivative thereof
  • concentrations of less that 5nm, for example 1-3nm or about 1 nm may be used in order to cause homodimerisation of the two caspase domains.
  • the chimeric protein may comprise a caspase domain fused to FKBP12 and is the interfacing protein may be a fusion of two or more FRB domains. These two or more FRB domains act as an interface, brining two FKBP12-Casp domains together.
  • the present invention provides a nucleic acid sequence which encodes a chimeric protein according to the first aspect of the invention.
  • the nucleic acid may be in the form of a nucleic acid construct, which comprises a plurality of nucleic acid sequences.
  • the construct may comprise one or more nucleic acid sequence(s) according to the second aspect of the invention and a nucleic acid sequence encoding a T-cell receptor (TCR) or chimeric antigen receptor (CAR).
  • TCR T-cell receptor
  • CAR chimeric antigen receptor
  • the nucleic acid construct may comprise:
  • a first nucleic acid sequence encoding a chimeric protein which comprises a caspase domain and a heterodimerization domain which comprises an FK506-binding protein (FKBP);
  • a second nucleic acid sequence encoding a chimeric protein which comprises a caspase domain and a heterodimerization domain which comprises an FRB domain of mTOR.
  • nucleic acid construct having the structure: Ht1-Casp-coexpr-Ht2-Ht2 wherein:
  • Casp is a nucleic acid sequence encoding a caspase domain
  • Ht 1 is a nucleic acid sequence encoding a first heterodimerization domain
  • Ht2 is a nucleic acid sequence encoding a second heterodimerization domain
  • coexpr is a nucleic acid sequence allowing co-expression of Ht1-Casp and Ht2-Ht2,
  • nucleic acid construct results in the production of a chimeric protein Ht1-Casp and an interfacing protein Ht2-Ht2 and wherein, in the presence of a chemical inducer of dimerization (CID), a pair of the chimeric proteins Ht1-Casp interact such that Ht1 from each chimeric protein heterodimerizes with an Ht2 domain from the interfacing protein, causing homodimerization of the two caspase domains.
  • CID chemical inducer of dimerization
  • Ht1 may comprise an FK506-binding protein (FKBP) and Ht2 may comprise an FRB domain of mTOR.
  • FKBP FK506-binding protein
  • the nucleic acid construct may also comprise a nucleic acid sequence encoding a T- cell receptor (TCR) or chimeric antigen receptor (CAR).
  • TCR T- cell receptor
  • CAR chimeric antigen receptor
  • the present invention provides a vector which comprises a nucleic acid sequence or a nucleic acid construct according to the second aspect of the invention.
  • the vector which may also comprise a nucleotide of interest, such as a nucleotide sequence encoding a chimeric antigen receptor or a T-cell receptor, such that when the vector is used to transduce a target cell, the target cell co-expresses a chimeric protein according to the first aspect of the invention and a chimeric antigen receptor or T-cell receptor.
  • the present invention provides a cell which expresses a chimeric protein according to the first aspect of the invention.
  • the cell may comprise:
  • a first chimeric protein which comprises a caspase domain and a heterodimerization domain which comprises an FK506-binding protein (FKBP); and
  • a second chimeric protein which comprises a caspase domain and a heterodimerization domain which comprises an FRB domain of mTOR.
  • a cell which expresses two proteins:
  • Ht1-Casp and Ht2-Ht2 wherein Ht1-Casp is a chimeric protein comprising a caspase domain (Casp) and a first heterodimerization domain (Ht1); and Ht2-Ht2 is an interfacing protein comprising two second heterodimerization domains (Ht2); and
  • a pair of the chimeric proteins Ht1-Casp9 interact such that Ht1 from each chimeric protein heterodimerizes with an Ht2 domain from the interfacing protein, causing homodimerization of the two caspase domains.
  • the cell may comprise a nucleic acid sequence or construct according to the second aspect of the invention.
  • the cell may, for example, be a haematopoietic stem cell, a lymphocyte or a T cell.
  • a method for making a cell according to the fourth aspect of the invention which comprises the step of transducing or transfecting a cell with a vector according to the third aspect of the invention.
  • a method for deleting a cell according to the fourth aspect of the invention which comprises the step of exposing the cells to a chemical inducer of dimerization (CID).
  • CID chemical inducer of dimerization
  • the CID may be rapamycin or a rapamycin analog.
  • a method for preventing or treating a disease in a subject which comprises the step of administering a cell according to the fourth aspect of the invention to the subject.
  • the method may comprise the following steps:
  • the method may be for treating cancer.
  • a method for preventing and/or treating an pathological immune reaction in a subject caused by administration of a cell according to the fourth aspect of the invention to the subject which comprises the step of administering rapamycin or a rapamycin analog to the subject.
  • the pathological immune reaction may be selected from the following group: graft- versus-host disease; on-target, off-tumour toxicity; immune activation syndrome; and lymphoproliferative disorders.
  • the method for treating or prevention a disease in a subject may comprise the following steps:
  • rapamycin or a rapamycin analog for use in haematopoietic stem cell transplantation, lymphocyte infusion or adoptive cell transfer.
  • rapamycin or a rapamycin analog for use in preventing or treating a pathological immune reaction caused by administration of a cell according to the fourth aspect of the invention to a subject.
  • the present invention provides a suicide gene which allows the selective destruction of adoptively infused cells in the face of unacceptable toxicity, and which is activated by rapamycin and/or its analogues.
  • Rapamycin is standard pharmaceutical with well understood properties, excellent bioavailability and volume of distribution and which is widely available. Rapamycin also does not aggravate the condition being treated, in fact, as it is an immunosuppressant it is likely to have a beneficial effect on unwanted toxicity as well as its suicide gene function.
  • the present invention relates to a chimeric protein which acts as a suicide gene.
  • Cells expressing the chimeric protein may be deleted in vivo or in vitro by administration of a chemical inducer of dimerization (CID) such as rapamycin or a rapamycin analogue.
  • CID chemical inducer of dimerization
  • the chimeric protein may have the formula: Ht1-Ht2-Casp in which
  • Casp is a caspase domain
  • Ht1 is a first heterodimerization domain
  • Ht2 is a second heterodimerization domain.
  • the chimeric protein may have the formula: Ht1-Ht2-L-Casp in which Casp, Ht1 and Ht2 are as defined above and L is an optional linker.
  • the configuration should be such that Ht1 does not significantly heterodimenze with Ht2 within the same chimeric protein molecule, but when two chimeric proteins come together in the presence of a chemical inducer of dimerization (CID) Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains.
  • CID chemical inducer of dimerization
  • the configuration is such that Ht1 does not heterodimenze to any significant extent with Ht2 within the same chimeric protein.
  • the presence of the CID should cause a greater proportion of dimerization between two chimeric proteins, than heterodimerization within the same chimeric protein.
  • the amount of chimeric proteins which are heterodimerized within the same molecule in a cell or cell population, or in solution may be less than 50%, 40%, 30%, 20%, 10%, 5% or 1 % of the amount of chimeric proteins which are heterdomerized with a separate chimeric protein molecule, in the presence of the CID.
  • the chimeric protein may comprise the sequence shown as SEQ ID No. 1.
  • FKBP12 refers to the sequence of FKBP12;
  • dCasp9 refers to the catalytic domain of Casp9;
  • L1 is a one repeat linker;
  • FMD-2A is a Foot and mouth disease 2A like peptide ERAV;
  • FRB is the FRB domain of mTOR;
  • L3 is a two repeat linker; and
  • FRBw is codon wobbled FRB
  • the invention provides a "two-molecule" suicide gene system, in which the CID is rapamycin or a rapamycin analogue.
  • the present invention also provides i) a chimeric protein which comprises a caspase domain and a heterodimerization domain which comprises an FK506-binding protein (FKBP12); and ii) a chimeric protein which comprises a caspase domain and a heterodimerization domain which comprises an FRB domain of mTOR.
  • FKBP12 FK506-binding protein
  • the chimeric protein may comprise the sequence shown as SEQ ID No. 2 or 3.
  • the invention provides an alternative "two molecule" approach, with a smaller footprint than the second embodiment.
  • Ht1 is fused with Caspase, and a second molecule comprises of Ht2-Ht2 fusion is co-expressed.
  • Ht2-Ht2 brings together two Ht1-Casp molecules.
  • this can be implemented by co-expressing FKBP12-Casp9 with FRB-FRB and activating with Rapamycin.
  • these components can be co-expressed with a foot- and-mouth disease 2A like peptide.
  • the second Ht2 (for example FRB) encoding sequence may be codon wobbled to prevent recombination.
  • FKBP12 refers to FKBP12
  • dCasp9 is the catalytic domain of Casp9
  • L1 is a one repeat linker
  • FMD-2A is a Foot and mouth disease 2A like peptide ERAV
  • FRB is the FRB domain of mTOR
  • L2 is a two repeat linker
  • FRBw is codon wobbled FRB.
  • Caspases or cysteine-aspartic proteases or cysteine-dependent aspartate-directed proteases are a family of cysteine proteases that play essential roles in apoptosis.
  • caspases have been identified in humans. There are two types of apoptotic caspases: initiator caspases and executioner caspases. Initiator caspases, such as caspase-2, caspase-8, caspase-9, and caspase-10, cleave inactive pro-forms of effector caspases, thereby activating them. Executioner caspases, such as caspase- 3, caspase-6 and caspase-7, then cleave other protein substrates within the cell, to trigger the apoptotic process.
  • Initiator caspases such as caspase-2, caspase-8, caspase-9, and caspase-10, cleave inactive pro-forms of effector caspases, thereby activating them.
  • Executioner caspases such as caspase- 3, caspase-6 and caspase-7, then cleave other protein substrates within the cell, to trigger the apoptotic process.
  • the caspase domain of the chimeric protein of the first aspect of the present invention may comprise an initiator caspase selected from caspase-2; caspase-8, caspase-9 and caspase-10; or an executioner caspase selected from caspase-3, caspase-6 and caspase-7.
  • the caspase domain of the chimeric protein of the first aspect of the present invention may comprise caspase-9.
  • Caspase 9 is the key initiator caspase so its activation is a very sensitive trigger for apoptosis induction. Furthermore, homodimerization is all that is required for activation, rather than homodimerization and proteolytic cleavage.
  • Full length caspase-9 has the sequence shown as SEQ ID No. 5.
  • Caspase-9 may be truncated, for example to remove the caspase recruitment domain. Truncated Caspase-9 is shown as SEQ ID No. 6
  • the chimeric protein of the first aspect of the invention may comprise SEQ ID No. 5 or SEQ ID No. 6 or a fragment or a variant thereof which retains the capacity to homodimerize and thus trigger apoptosis.
  • a variant caspase-9 sequence may have at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity to SEQ ID No. 5 or 6.
  • protease caspase 9 is the central participant in a multi-component pathway known as the apoptosome, which controls cell deletion during embryogenesis, and physiological responses that trigger cell death as well as lethal cellular insults such as ionizing radiation or chemotherapeutic drugs.
  • the function of caspase 9 is to generate the active forms of caspases 3 and 7 by limited proteolysis, and thereby transmit the apoptotic signal to the execution phase.
  • caspase 9 is unusual among its close relatives in that proteolysis between the large and small subunit does not convert the latent zymogen to the catalytic form. In fact, it is homodimerization which is required for activation.
  • rapamycin and FK506 act by inducing the heterodimerization of cellular proteins. Each drug binds with a high affinity to the FKBP12 protein, creating a drug-protein complex that subsequently binds and inactivates mTOR/FRAP and calcineurin, respectively.
  • FKBP-rapamycin binding (FRB) domain of mTOR has been defined and applied as an isolated 89 amino acid protein moiety that can be fused to a protein of interest. Rapamycin can then induce the approximation of FRB fusions to FKBP12 or proteins fused with FKBP 12.
  • heterodimerization domains may be or comprise FRB, or a variant thereof and the other heterodimerization domain (Ht2 or Ht1) may be or comprise FKBP12 or a variant thereof.
  • Rapamycin has several properties of an ideal dimerizer: it has a high affinity (KD ⁇ 1 nM) for FRB when bound to FKBP12, and is highly specific for the FRB domain of mTOR. Rapamycin is an effective therapeutic immunosuppressant with a favourable pharmacokinetic and pharmacodynamics profile in mammals. Pharmacological analogues of Rapamycin with different pharmacokinetic and dynamic properties such as Everolimus, Temsirolimus and Deforolimus (Benjamin et al, Nature Reviews, Drug Discovery, 2011) may also be used according to the clinical setting.
  • the surface of rapamycin which contacts FRB may be modified.
  • Compensatory mutation of the FRB domain to form a burface that accommodates the "bumped" rapamycin restores dimerizing interactions only with the FRB mutant and not to the endogenous mTOR protein.
  • Bayle et al. (Chem Bio; 2006; 13; 99-107) describes various rapamycin analogs, or "rapalogs" and their corresponding modified FRB binding domains.
  • Bayle et al. (2006) describes the rapalogs: C-20-methyllyrlrapamycin (MaRap), C16(S)-Butylsulfonamidorapamycin (C16-BS-Rap) and C16-(S)-7- methylindolerapamycin (AP21976/C16-AiRap), as shown in Figure 3, in combination with the respective complementary binding domains for each.
  • Other rapamycins/rapalogs include sirolimus and tacrolimus.
  • heterodimerization domains of the chimeric protein may be or comprise one the sequences shown as SEQ ID NO: 7 to SEQ ID NO: 1 1 , or a variant thereof.
  • Variant sequences may have at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity to SEQ ID No. 7 to 1 1 , provided that the sequences provide an effective dimerization system. That is, provided that the sequences facilitate sufficient co- localisation of the two chimeric proteins to allow homodimerization of the two caspase domains.
  • the "wild-type" FRB domain shown as SEQ ID No. 8 comprises amino acids 2025- 21 14 of human mTOR.
  • the FRB sequence of the chimeric protein of the invention may comprise an amino acid substitution at one of more of the following positions: 2095, 2098, 2101.
  • the variant FRB used in the chimeric protein of the invention may comprise one of the following amino acids at positions 2095, 2098 and 2101 : 2095: K, P, T or A
  • Bayle et al (as above) describe the following FRB variants, annotated according to the amino acids at positions 2095, 2098 and 2101 (see Table 1): KTW, PLF, KLW, PLW, TLW, ALW, PTF, ATF, TTF, KLF, PLF, TLF, ALF, KTF, KHF, KFF, KLF.
  • These variants are capable of binding rapamycin and rapalogs to varying extents, as shown in Table 1 and Figure 5A of Bayle et al.
  • the chimeric protein of the invention may comprise one of these FRB variants.
  • a linker may be included to spatially separate the caspase domain and the heterodimerization domain(s).
  • the chimeric protein comprises two heterodimerization domains which are held in a configuration such that they cannot heterodimerize with each other in the presence of the CI D in a single molecule, but Ht1 on one molecule can heterodimerise with Ht2 on another chimeric molecule having the same heterodimerization domains ( Figure 1 B).
  • Ht1 and Ht2 flank the Caspase domain (Ht1-Casp-Ht2)
  • activation was inferior to designs where Ht1 and Ht2 were linked together, indicating the importance of preventing non-productive binding of Ht1 and Ht2 from a single molecule to a single CID.
  • the linker (L1) should provide sufficient flexibility so that the catalytic domains can homodimerize, but not so much flexibility that the energic barrier to homodimerization is not overcome ( Figure 1).
  • the linker may be less than 15, less than 10 or between 5-15 or 5-10 amino acids in length.
  • the chimeric protein comprises a single heterodimerization domain, which is capable of heterodimerization with a complementary heterodimerization domain on a second chimeric protein in the presence of a CID.
  • the two heterodimerisation domains may be provided on a signle molecule with a long linker (L2), providing a construct having the formula:
  • the HT and Casp domains may be in either order on each side of the linker.
  • the linker L2 may confer sufficient flexibility so the first heterodimerization domain can heterodimerize with the second heterodimerization domain; and so that the caspase domain in the part of the molecule corresponding to the 'first chimeric protein' can homodimerize with the caspase domain in the part of the molecule corresponding to the 'second chimeric protein'.
  • Casp is fused to a single heterodimerization domain, but a second molecule which is a fusion of two or more copies of the other heterodimerization domain.
  • the two molecules may be co- expressed.
  • the second molecule acts as an interface bringing two or more Casp domains together in the presence of CID.
  • the two or more copies of heterodimerization domains must be fused in such a way to allow approximation of the Casp9 domains sufficiently to activate them.
  • the interfacing protein may be multimeric, comprising more than two Ht2 domains.
  • the interfacing protein may have the formula Ht2-L2-Ht2, or Ht2 - L2 in which L2 is a coiled-coil domain.
  • a coiled coil is a structural motif in which two to seven alpha-helices are wrapped together like the strands of a rope.
  • the structure of coiled coil domains is well known in the art. For example as described by Lupas & Gruber (Advances in Protein Chemistry; 2007; 70; 37-38).
  • Coiled coils usually contain a repeated pattern, hxxhcxc, of hydrophobic (h) and charged (c) amino-acid residues, referred to as a heptad repeat.
  • the positions in the heptad repeat are usually labeled abcdefg, where a and d are the hydrophobic positions, often being occupied by isoleucine, leucine, or valine. Folding a sequence with this repeating pattern into an alpha-helical secondary structure causes the hydrophobic residues to be presented as a 'stripe' that coils gently around the helix in left-handed fashion, forming an amphipathic structure.
  • proteins which contain a coiled coil domain include, but are not limited to, kinesin motor protein, hepatitis D delta antigen, archaeal box C/D sRNP core protein, cartilage-oligomeric matrix protein (COMP), mannose-binding protein A, coiled-coil serine-rich protein 1 , polypeptide release factor 2, SNAP-25, SNARE, Lac repressor or apolipoprotein E.
  • kinesin motor protein hepatitis D delta antigen
  • archaeal box C/D sRNP core protein cartilage-oligomeric matrix protein (COMP)
  • mannose-binding protein A coiled-coil serine-rich protein 1
  • polypeptide release factor 2 SNAP-25
  • SNARE SNARE
  • Lac repressor or apolipoprotein E.
  • the chemical inducer of dimerization may be any molecule which induces heterodimerization between Ht1 and Ht2 on separate chimeric molecules having the same Ht1 and Ht2 domains.
  • the CID may be rapamycin or a rapamycin analog ("rapalogs") which have improved or differing pharmadynamic or pharmacokinetic properties to rapamycin but have the same broad mechanism of action.
  • the CID may be an altered rapamycin with engineered specificity for complementary FKBP12 or FRB - for example as shown in Figure 4.
  • Bayle et al 2006, as above describes various rapalogs functionalised at C16 and/or C20.
  • Examples of such rapalogs in the first category include Sirolimus, Everolimus, Temsirolimus and Deforolimus.
  • Examples of rapalogs in the second category include C-20-methyllyrlrapamycin (MaRap); C16(S)-Butylsulfonamidorapamycin (C16-BS- Rap); C16-(S)-3-mehylindolerapamycin (C16-iRap); and C16-(S)-7- methylindolerapamycin (AP21976/C16-AiRap).
  • caspase activation which is 2, 5, 10, 50, 100, 1 ,000 or 10,000-fold higher than the caspase activity which occurs in the absence of CID.
  • Rapamycin is a potent immunsuppressive agent.
  • Analogues of rapamycin are in every day clinical use. Modern rapalogues have excellent bioavailability and volumes of distribution. Although they are potent immunsuppressive agents, a short dose (to activate a suicide gene) should have minimal side-effects. Further, unlike administration of a mAb, the pharmacological effects of rapamycin and analogues may well be advantageous in clinical scenarios where suicide genes require activation, such as off-tumour toxicity or immune hyperactivation syndromes. NUCLEIC ACID SEQUENCES
  • the second aspect of the invention provides a nucleic acid sequence which encodes a chimeric protein according to the invention.
  • polynucleotide As used herein, the terms “polynucleotide”, “nucleotide”, and “nucleic acid” are intended to be synonymous with each other.
  • Nucleic acids according to the second aspect of the invention may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the use as described herein, it is to be understood that the polynucleotides may be modified by any method available in the art.
  • variants may be carried out in order to enhance the in vivo activity or life span of polynucleotides of interest.
  • variants include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence.
  • Ht1 is a first heterodimerization domain
  • Ht2 is a second heterodimerization domain.
  • L is an optional linker
  • Casp is a caspase domain;
  • the nucleic acid sequence may encode the chimeric protein sequence shown as SEQ ID No. 1 or a variant thereof.
  • nucleotide sequence may comprise the sequence shown as SEQ ID No. 12
  • nucleic acid sequence encoding a chimeric protein having the formula: Ht1-L-Casp wherein
  • Ht1 is a heterodimerization domain.
  • L is an optional linker
  • Casp is a caspase domain
  • the nucleic acid sequence may encode the chimeric protein sequence shown SEQ ID No. 2 or 3 or a variant thereof.
  • nucleotide sequence may comprise the sequence shown as SEQ ID No. 13 or 14 SEQ ID No. 13 (FKBP12-dCasp9)
  • nucleic acid sequences may be provided in the form of a construct which encodes both chimeric proteins.
  • the construct may encode a polyprotein having the formula:
  • Ht1 is a first heterodimerization domain
  • L1 and L2 are optional linkers which may be the same or different;
  • Coexpr is a sequence enabling coexpression of the two proteins: Ht1-L1-Casp and
  • Ht2 is a second heterodimerization domain
  • Casp is a caspase domain
  • nucleic acid sequences encoding the same or similar sequences such as the two caspase domains
  • one of the sequences may be codon wobbled to avoid homologous recombination.
  • nucleic acid sequence which encodes a sequence with the following formula: Ht1-Casp-coexpr-Ht2-Ht2 wherein
  • Casp is a caspase domain
  • Ht1 is a first heterodimerization domain
  • Coexpr is a sequence enabling coexpression of the proteins Ht1-Casp and Ht2-Ht2, such as a cleavage site;
  • Ht2 is a second heterodimerisation domain, which heterodimerises with Ht1 in the presence of a chemical inducer of dimerization (CID).
  • CID chemical inducer of dimerization
  • one of the sequences encoding Ht2 may be codon wobbled, in order to avoid homologous recombination.
  • the nucleic acid construct according to the third embodiment may have the sequence shown as SEQ ID No. 15.
  • Nucleic acid sequences with a high degree of similarity such as the caspase sequence(s) or FRB sequences may be codon wobbled to avoid recombination.
  • the invention also provides a nucleic acid construct which comprises:
  • a first nucleic acid sequence encoding a chimeric protein which comprises a caspase domain and a heterodimerization domain which comprises an FK506-binding protein (FKBP);
  • a second nucleic acid sequence encoding a chimeric protein which comprises a caspase domain and a heterodimerization domain which comprises an FRB domain of mTOR.
  • the invention also provides a nucleic acid construct which comprises a nucleic acid sequence encoding one or more chimeric protein(s) and a further nucleic acid sequence of interest (NOI).
  • NOI may, for example encode a T-cell receptor (TCR) or chimeric antigen receptor (CAR).
  • the nucleic acid sequences may be joined by a sequence allowing co-expression of the two or more nucleic acid sequences.
  • the construct may comprise an internal promoter, an internal ribosome entry sequence (IRES) sequence or a sequence encoding a cleavage site.
  • IRS internal ribosome entry sequence
  • the cleavage site may be self-cleaving, such that when the polypeptide is produced, it is immediately cleaved into the discrete proteins without the need for any external cleavage activity.
  • Various self-cleaving sites are known, including the Foot-and-Mouth disease virus (FMDV) 2a self-cleaving peptide, which has the sequence shown as SEQ ID No. 16 or 17: SEQ ID No. 16
  • the co-expressing sequence may be an internal ribosome entry sequence (IRES).
  • the co-expressing sequence may be an internal promoter.
  • TCR T-CELL RECEPTOR
  • T cell receptor or TCR is a molecule found on the surface of T cells that is responsible for recognizing antigens bound to major histocompatibility complex (MHC) molecules.
  • MHC major histocompatibility complex
  • the binding between TCR and antigen is of relatively low affinity and is degenerate: many TCR recognize the same antigen and many antigens are recognized by the same TCR.
  • the TCR is composed of two different protein chains, i.e. it is a heterodimer. In 95% of T cells, this consists of an alpha (a) and beta ( ⁇ ) chain, whereas in 5% of T cells this consists of gamma and delta ( ⁇ / ⁇ ) chains. This ratio changes during ontogeny and in diseased states.
  • the T lymphocyte When the TCR engages with antigenic peptide and MHC (peptide/MHC), the T lymphocyte is activated through a series of biochemical events mediated by associated enzymes, co-receptors, specialized adaptor molecules, and activated or released transcription factors.
  • the nucleic acid construct or vector of the present invention may comprise a nucleic acid sequence encoding a TCR a chain, a TCR ⁇ chain, a TCRy chain or a TCR ⁇ chain. It may, for example, comprise a nucleic acid sequence encoding a TCR a chain and a nucleic acid sequence encoding a TCR ⁇ chain; or a a nucleic acid sequence encoding a TCRY chain or a nucleic acid sequence encoding a TCR ⁇ chain.
  • the two nucleic acid sequences may be joined by a sequence enabling co- expression of the two TCR chains, such as an internal promoter, an I RES sequence or a cleavage site such as a self-cleaving site.
  • the nucleic acid sequence of interest may encode a chimeric antigen receptor (CAR).
  • CAR chimeric antigen receptor
  • Classical CARs are chimeric type I trans-membrane proteins which connect an extracellular antigen-recognizing domain (binder) to an intracellular signalling domain (endodomain).
  • the binder is typically a single-chain variable fragment (scFv) derived from a monoclonal antibody (mAb), but it can be based on other formats which comprise an antigen binding site such as a ligand.
  • scFv single-chain variable fragment
  • mAb monoclonal antibody
  • a spacer domain may be necessary to isolate the binder from the membrane and to allow it a suitable orientation.
  • a common spacer domain used is the Fc of IgGl More compact spacers can suffice e.g. the stalk from CD8a and even just the lgG1 hinge alone, depending on the antigen.
  • a trans-membrane domain anchors the protein in the cell membrane and connects the spacer to the endodomain which may comprise or associate with an intracellular signalling domain.
  • CAR-encoding nucleic acids may be transferred to T cells using, for example, retroviral vectors. In this way, a large number of antigen-specific T cells can be generated for adoptive cell transfer. When the CAR binds the target-antigen, this results in the transmission of an activating signal to the T-cell it is expressed on. Thus the CAR directs the specificity and cytotoxicity of the T cell towards cells expressing the targeted antigen.
  • the present invention provides a vector which comprises a nucleic acid sequence or nucleic acid construct of the invention.
  • the present invention also provides a vector, or kit of vectors which comprises one or more nucleic acid sequence(s) or nucleic acid construct(s) of the invention and optionally one of more additions nucleic acid sequences of interest (NOI).
  • a vector may be used to introduce the nucleic acid sequence(s) or nucleic acid construct(s) into a host cell so that it expresses one or more chimeric protein(s) according to the first aspect of the invention and optionally one or more other proteins of interest (POI).
  • the kit may also comprise a CID.
  • the vector may, for example, be a plasmid or a viral vector, such as a retroviral vector or a lentiviral vector, or a transposon based vector or synthetic mRNA.
  • the vector may be capable of transfecting or transducing a T cell.
  • the NOI may, for example encode a chimeric antigen receptor or a T-cell receptor, such that when the vector is used to transduce a target cell, the target cell co- expresses a chimeric protein and a chimeric antigen receptor or T-cell receptor.
  • the present invention also relates to a cell comprising a chimeric protein according to the first aspect of the invention.
  • the cell may express a chimeric protein having two heterodimerization domains, according ot the first embodiment of the first aspect of the present invention.
  • the cell may express two chimeric proteins; one which comprises a caspase domain and a heterodimerization domain which comprises an FK506-binding protein (FKBP); and one which comprises a caspase domain and a heterodimerization domain which comprises an FRB domain of mTOR, according to the second embodiment of the first aspect of the invention.
  • FKBP FK506-binding protein
  • Ht1-Casp expresses two proteins: Ht1-Casp and Ht2-Ht2 in which Ht1-Casp is a chimeric protein comprising a caspase domain (Casp) and a first heterodimerization domain (Ht1); and Ht2-Ht2 is an interfacing protein comprising two second heterodimerization domains (Ht2)
  • the cell may, for example, be an immune cell such as a T-cell or a natural killer (NK) cell.
  • a chemical inducer of dimerization CID
  • a pair of the chimeric proteins Ht1-Casp9 interact such that Ht1 from each chimeric protein heterodimerizes with an Ht2 domain from the interfacing protein, causing homodimerization of the two caspase domains (see Figure 1d).
  • the cell may, for example, be an immune cell such as a T-cell or a natural killer (NK) cell.
  • the cell may be a stem cell such as a haematopoietic stem cell.
  • T cells or T lymphocytes which are a type of lymphocyte that play a central role in cell-mediated immunity. They can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on the cell surface.
  • TCR T-cell receptor
  • TH cells Helper T helper cells (TH cells) assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages.
  • TH cells express CD4 on their surface.
  • TH cells become activated when they are presented with peptide antigens by MHC class II molecules on the surface of antigen presenting cells (APCs). These cells can differentiate into one of several subtypes, including TH1 , TH2, TH3, TH17, Th9, or TFH, which secrete different cytokines to facilitate different types of immune responses. Cytolytic T cells (TC cells, or CTLs) destroy virally infected cells and tumor cells, and are also implicated in transplant rejection. CTLs express the CD8 at their surface. These cells recognize their targets by binding to antigen associated with MHC class I, which is present on the surface of all nucleated cells.
  • APCs antigen presenting cells
  • Memory T cells are a subset of antigen-specific T cells that persist long-term after an infection has resolved. They quickly expand to large numbers of effector T cells upon re-exposure to their cognate antigen, thus providing the immune system with "memory" against past infections.
  • Memory T cells comprise three subtypes: central memory T cells (TCM cells) and two types of effector memory T cells (TEM cells and TEMRA cells). Memory cells may be either CD4+ or CD8+. Memory T cells typically express the cell surface protein CD45RO.
  • Treg cells Regulatory T cells
  • suppressor T cells are crucial for the maintenance of immunological tolerance. Their major role is to shut down T cell- mediated immunity toward the end of an immune reaction and to suppress autoreactive T cells that escaped the process of negative selection in the thymus.
  • Treg cells Two major classes of CD4+ Treg cells have been described—natural occurring Treg cells and adaptive Treg cells.
  • Naturally occurring Treg cells arise in the thymus and have been linked to interactions between developing T cells with both myeloid (CD1 1c+) and plasmacytoid (CD123+) dendritic cells that have been activated with TSLP.
  • Naturally occurring Treg cells can be distinguished from other T cells by the presence of an intracellular molecule called FoxP3. Mutations of the FOXP3 gene can prevent regulatory T cell development, causing the fatal autoimmune disease IPEX.
  • Adaptive Treg cells may originate during a normal immune response.
  • Natural Killer Cells or NK cells are a type of cytolytic cell which form part of the innate immune system. NK cells provide rapid responses to innate signals from virally infected cells in an MHC independent manner NK cells (belonging to the group of innate lymphoid cells) are defined as large granular lymphocytes (LGL) and constitute the third kind of cells differentiated from the common lymphoid progenitor generating B and T lymphocytes. NK cells are known to differentiate and mature in the bone marrow, lymph node, spleen, tonsils and thymus where they then enter into the circulation.
  • Stem cells are undifferentiated cells which can differentiate into specialized cells. In mammals, there are two broad types of stem cells: embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing adult tissues. In a developing embryo, stem cells can differentiate into all the specialized cells— ectoderm, endoderm and mesoderm (see induced pluripotent stem cells)— but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues. There are three known accessible sources of autologous adult stem cells in humans:
  • Bone marrow which requires extraction by harvesting, i.e. drilling into bone.
  • Adipose tissue which requires extraction by liposuction.
  • Blood which requires extraction through apheresis, wherein blood is drawn from the donor and passed through a machine that extracts the stem cells and returns other portions of the blood to the donor.
  • HSCs Hematopoietic stem cells
  • the hematopoietic tissue contains cells with long- term and short-term regeneration capacities and committed multipotent, oligopotent, and unipotent progenitors.
  • HSCs are a heterogeneous population.
  • My-bi Myeloid- biased HSC have low L/M ratio (between 0 and 3), whereas lymphoid-biased (Ly-bi) HSC show a large ratio (>10).
  • the third category consists of the balanced (Bala) HSC, whose L/M ratio is between 3 and 10. Only the myeloid-biased and balanced HSCs have durable self-renewal properties.
  • the chimeric protein-expressing cells of the invention may be any of the cell types mentioned above.
  • T or NK cells expressing one or more chimeric protein(s) according to the first aspect of the invention may either be created ex vivo either from a patient's own peripheral blood (1 st party), or in the setting of a haematopoietic stem cell transplant from donor peripheral blood (2 nd party), or peripheral blood from an unconnected donor (3 rd party).
  • T or NK cells expressing one or more chimeric protein(s) according to the first aspect of the invention may be derived from ex vivo differentiation of inducible progenitor cells or embryonic progenitor cells to T cells.
  • an immortalized T-cell line which retains its lytic function and could act as a therapeutic may be used.
  • chimeric protein(s)-expressing cells are generated by introducing DNA or RNA coding for the, or each, chimeric protein, and optionally an NOI by means such as transduction with a viral vector or transfection with DNA or RNA.
  • the cell of the invention may be an ex vivo T or NK cell from a subject.
  • the T or NK cell may be from a peripheral blood mononuclear cell (PBMC) sample.
  • PBMC peripheral blood mononuclear cell
  • T or NK cells may be activated and/or expanded prior to being transduced with nucleic acid encoding one or more chimeric protein(s) according to the first aspect of the invention, for example by treatment with an anti-CD3 monoclonal antibody.
  • the T or NK cell of the invention may be made by:
  • the present invention also provides a kit which comprises a T or NK cell comprising one or more chimeric protein(s) according to the first aspect of the invention and a CID.
  • the present invention also relates to a pharmaceutical composition containing a plurality of cells according to the fourth aspect of the invention.
  • the pharmaceutical composition may additionally comprise a pharmaceutically acceptable carrier, diluent or excipient.
  • the pharmaceutical composition may optionally comprise one or more further pharmaceutically active polypeptides and/or compounds.
  • Such a formulation may, for example, be in a form suitable for intravenous infusion.
  • the invention also provides a method for making a cell according to the fourth aspect of the invention which comprises the step of transducing or transfecting a cell with a vector according to the third aspect of the invention.
  • the vector may, for example, be a retroviral or lentiviral vector.
  • the invention also provides a method for deleting a cell according to the fourth aspect of the invention, which comprises the step of exposing the cells to the CID, such as rapamycin or a rapamycin analog.
  • the cells may be exposed to the CID in vivo or in vitro. Deletion of the cell may be caused by apoptosis induced by caspase activation, following CID-induced homodimerization of the caspase domains.
  • the CID may be administered in the form of a pharmaceutical composition.
  • the pharmaceutical composition may additionally comprise a pharmaceutically acceptable carrier, diluent or excipient.
  • the pharmaceutical composition may optionally comprise one or more further pharmaceutically active polypeptides and/or compounds.
  • Such a formulation may, for example, be in a form suitable for intravenous infusion.
  • the invention also provides a method for preventing and/or treating an pathological immune reaction in a subject caused by administration of a cell according to the fourth aspect of the invention to the subject, which comprises the step of administering a CID, such as rapamycin or a rapamycin analog to the subject.
  • a CID such as rapamycin or a rapamycin analog
  • the pathological immune reaction may be selected from the following group: graft- versus-host disease; on-target, off-tumour toxicity; immune activation syndrome; and lymphoproliferative disorders.
  • the invention also provides a method for treating or preventing a disease in a subject, which comprises the step of administering a cell according to the fourth aspect of the invention to the subject.
  • the cell may be in the form of a pharmaceutical composition as defined above.
  • the method may comprises the following steps:
  • a method for treating a disease relates to the therapeutic use of the cells of the present invention.
  • the cells may be administered to a subject having an existing disease or condition in order to lessen, reduce or improve at least one symptom associated with the disease and/or to slow down, reduce or block the progression of the disease.
  • the method for preventing a disease relates to the prophylactic use of the immune cells of the present invention.
  • such cells may be administered to a subject who has not yet contracted the disease and/or who is not showing any symptoms of the disease to prevent or impair the cause of the disease or to reduce or prevent development of at least one symptom associated with the disease.
  • the subject may have a predisposition for, or be thought to be at risk of developing, the disease.
  • the methods for treating a disease provided by the present invention may involve monitoring the progression of the disease and monitoring any toxic activity and adjusting the dose of the CID administered to the subject to provide acceptable levels of disease progression and toxic activity.
  • Monitoring the progression of the disease means to assess the symptoms associated with the disease over time to determine if they are reducing/improving or increasing/worsening.
  • Toxic activities relate to adverse effects caused by the cells of the invention following their administration to a subject.
  • Toxic activities may include, for example, immunological toxicity, biliary toxicity and respiratory distress syndrome.
  • the invention provides a method for treating a disease in a subject, which comprises the following steps:
  • the present invention provides a cell of the present invention for use in treating and/or preventing a disease.
  • the cell may, for example, be for use in haematopoietic stem cell transplantation, lymphocyte infusion or adoptive cell transfer.
  • the invention also relates to the use of a cell of the present invention in the manufacture of a medicament for the treatment and/or prevention of a disease.
  • the present invention also provides a CID agent capable inducing dimerizing a chimeric protein according to the first aspect of the invention for use in treating and/or preventing a toxic activity.
  • the present invention also provides a CID agent for use in activating a pair of caspase domains of chimeric proteins according to the first aspect of the invention in a cell.
  • the disease to be treated and/or prevented by the cells and methods of the present invention may be an infection, such as a viral infection.
  • the methods of the invention may also be for the control of pathogenic immune responses, for example in autoimmune diseases, allergies and graft-vs-host rejection.
  • the cells of the invention express a TCR or CAR
  • they may be useful for the treatment of a cancerous disease, such as bladder cancer, breast cancer, colon cancer, endometrial cancer, kidney cancer (renal cell), leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, pancreatic cancer, prostate cancer and thyroid cancer.
  • a cancerous disease such as bladder cancer, breast cancer, colon cancer, endometrial cancer, kidney cancer (renal cell), leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, pancreatic cancer, prostate cancer and thyroid cancer.
  • the TCR/CAR-expressing cells of the present invention may be capable of killing target cells, such as cancer cells.
  • the invention also provides rapamycin or a rapamycin analogue for use in preventing or treating a pathological immune reaction caused by administration of a cell according to the fourth aspect of the invention to a subject.
  • the cells of the present invention may be used in any cellular therapy in which modified or unmodified cells are administered to a patient.
  • An example of a cellular therapy is adoptive T cell transfer after CD34+ stem cell transplantation. Administering T cells after stem cell transfer helps to accelerate the reconstitution of an immune system in the patient recipient.
  • a matched related or unrelated donor is not available, or the disease is too aggressive for an extensive donor search, the use of an HLA haploidentical family donor may be effective.
  • Such donors may be parents, siblings, or second-degree relatives.
  • Such infusions may enhance immune recovery and thereby reduce virus infections and eliminate relapsing leukemia cells.
  • graft-versus-host disease may cause graft-versus-host disease (GvHD) in which the donor cells react against the recipient, which may progressively damage the skin, gut, liver, and other organs of the recipient.
  • cell therapies include using native cells or cells genetically engineered to express a heterologous gene. These treatments are used for many disorders, including blood disorders, but these therapies may have negative side effects.
  • immature progenitor cells that can differentiate into many types of mature cells, such as, for example, mesenchymal stromal cells, may be used to treat disorders by replacing the function of diseased cells.
  • There present invention provides a rapid and effective mechanism to remove possible negative effects of donor cells used in cellular therapy.
  • the present invention provides a method of reducing the effect of graft versus host disease in a human patient following donor T cell transplantation, comprising transfecting or transducing human donor T cells in a donor cell culture with vector according to the present invention; administering the transduced or transfected donor T cells to the patient; subsequently detecting the presence or absence of graft versus host disease in the patient; and administering a chemical inducer of dimerization (CID) to a patient for whom the presence of graft versus host disease is detected.
  • the T cells may be non-allodepleted.
  • the present invention provides a method of stem cell transplantation, comprising administering a haploidentical stem cell transplant to a human patient; and administering haploidentical donor T cells to the patient, wherein the T cells are transfected or transduced in a haploidentical donor cell culture with a vector according to the invention.
  • the cells may be non-allodepleted human donor T cells in a donor cell culture.
  • the present invention also provides a method of stem cell transplantation, comprising administering a haploidentical stem cell transplant to a human patient; and administering non-allodepleted haploidentical donor T cells to the patient, wherein the T cells are transfected or transduced in a haploidentical donor cell culture with vector according to the invention.
  • the haploidentical stem cell transplant may be a CD34+ haploididentical stem cell transplant.
  • the human donor T cells may be haploidentical to the patient's T cells.
  • the patient may any disease or disorder which may be alleviated by stem cell transplantation.
  • the patient may have cancer, such as a solid tumour or cancer of the blood or bone marrow.
  • the patient may have a blood or bone marrow disease.
  • the patient may have sickle cell anemia or metachromatic leukodystrophy.
  • the donor cell culture may be prepared from a bone marrow sample or from peripheral blood.
  • the donor cell culture may be prepared from donor peripheral blood mononuclear cells.
  • the donor T cells are allodepleted from the donor cell culture before transfection or transduction.
  • Transduced or transfected T cells may be cultured in the presence of IL-2 before administration to the patient.
  • Example 1 Production of T-cells expressing chimeric proteins T-cells were transduced with the different constructs.
  • T-cells were transduced with two vectors: one coding for FKBP12-Casp9 co-expressed with the green fluorescent protein eGFP by means of an internal ribosome entry sequence, and the other coding for FRB-Casp9 co-expressed with the blue fluorescent protein eBFP2.
  • rapCasp9 Figure 1 b
  • T-cells were transduced with just one vector coding for the respective rapCasp9 which are co-expressed eGFP.
  • a construct which provided FKB12-Casp9 and FRB-FRBw was encoded in a tri-cistronic cassette whereby the FKBP12-Casp9 and FRB-FRBw were co-expressed using a FMD-2A like peptide and eGFP was co-expressed with an IRES.
  • the T-cells were intentionally only partially transduced so within the cell culture a proportion of cells remained non-transduced to act as an internal negative control. As a further control, T-cells were transduced with a vector which codes for eGFP alone to exclude non-specific effects of Rapamycin on transduced cells.
  • T-cells were exposed to different concentrations of Rapamycin and incubated for 48 hours. Following this, T-cells were stained with Annexin-V and 7AAD and analysed by flow- cytometry. By gating on the live cells, and interrogating the population of cells expressing fluorescent proteins, survival of the transduced and non-transduced populations could be clearly measured.
  • the dual FRB-Casp9 and FKBP12-Casp9 approach resulted in effective deletion of only double positive cells as expected.
  • the FKBP12-FRB-Casp9 construct resulted in effective deletion of single positive cells.
  • the FKBP12-Casp9-FRB construct resulted in minimal deletion.
  • the FKBP12- Casp9/FRB-FRBw resulted in effective deletion of single positive cells.
  • the control resulted in no specific deletion ( Figures 2 and 3).
  • the constructs shown in Figure 5 we generated and transduced into Jurkat cells. Transduced cells were mixed with non-transduced (NT) cells to have both construct positive and negative cells within the population. Rapamycin was added at a concentration of 0, 1 , 10, 100 and 1000 nM and the cells were incubated for 24h. Following harvesting, the cells were stained with PI and annexin V and analysed by FACS. The results are shown in Figures 6 to 9 and summarised in Figure 10.
  • the pair of constructs having a configuration as defined according to the second embodiment of the first aspect of the invention, namely MP20206 and MP20207 also performed very well, giving very efficient killing of transfected cells at all concentrations of rapamycin above and including 1 nM.
  • Constructs having a configuration as defined according to the fourth embodiment of the first aspect of the invention namely MP20263, MP20264 and MP21067 prefomed well at 1 nM rapamycin, but at higher concentrations of rapamycin killing was less efficient.
  • Cells at a concentration of with 2X10 5 cells per well were either left untreated, or were treated with rapamycin or temsirolimus at the following concentrations: 0.01 , 0.1 , 1 , 10nM (of either rapamycin or temsirolimus) Cells were incubated for 24h and were then stained for Annexin V and PI and were analysed by FACS. The results are shown in Figure 1 1.
  • the construct MP20244 which has a configuration as defined according to the first embodiment of the first aspect of the invention; and the pair of constructs MP20206 and MP20207, having a configuration as defined according to the second embodiment of the first aspect of the invention, both performed well. Both gave efficient killing of transfected cells at all concentrations of temsirolimus above and including 1 nM.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
PCT/GB2016/050451 2015-02-24 2016-02-23 Chimeric protein WO2016135470A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
RU2017132293A RU2746755C2 (ru) 2015-02-24 2016-02-23 Химерный белок
DK16707195.0T DK3197453T3 (da) 2015-02-24 2016-02-23 Kimært protein
CN202211656921.4A CN116425882A (zh) 2015-02-24 2016-02-23 嵌合蛋白
EP16707195.0A EP3197453B9 (en) 2015-02-24 2016-02-23 Chimeric protein
US15/526,097 US10098911B2 (en) 2015-02-24 2016-02-23 Chimeric protein
AU2016225190A AU2016225190B2 (en) 2015-02-24 2016-02-23 Chimeric protein
CA2973107A CA2973107A1 (en) 2015-02-24 2016-02-23 Chimeric protein
EP22191585.3A EP4147696A1 (en) 2015-02-24 2016-02-23 Chimeric protein
PL16707195.0T PL3197453T3 (pl) 2015-02-24 2016-02-23 Białko chimeryczne
JP2017542093A JP6836508B2 (ja) 2015-02-24 2016-02-23 キメラタンパク質
KR1020237038544A KR20230156817A (ko) 2015-02-24 2016-02-23 키메라 단백질
BR112017013689-9A BR112017013689A2 (pt) 2015-02-24 2016-02-23 proteína quimérica
MX2017007848A MX2017007848A (es) 2015-02-24 2016-02-23 Proteina quimerica.
CN201680006920.1A CN107207621B (zh) 2015-02-24 2016-02-23 嵌合蛋白
SG11201705300VA SG11201705300VA (en) 2015-02-24 2016-02-23 Chimeric protein
KR1020177025985A KR102601849B1 (ko) 2015-02-24 2016-02-23 키메라 단백질
ES16707195T ES2930623T3 (es) 2015-02-24 2016-02-23 Proteína quimérica
IL252840A IL252840B (en) 2015-02-24 2017-06-12 A chimeric protein, a nucleic acid sequence, a nucleic acid construct, a vector, a cell, a method for making a cell, a method for deleting a cell, a cell for use, rapamycin ser a rapamycin analogue for use
ZA2017/04231A ZA201704231B (en) 2015-02-24 2017-06-21 Chimeric protein
US16/113,098 US10478457B2 (en) 2015-02-24 2018-08-27 Chimeric protein
US16/598,652 US11103532B2 (en) 2015-02-24 2019-10-10 Chimeric protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1503133.9 2015-02-24
GB201503133A GB201503133D0 (en) 2015-02-24 2015-02-24 Chimeric protein

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/526,097 A-371-Of-International US10098911B2 (en) 2015-02-24 2016-02-23 Chimeric protein
US16/113,098 Continuation US10478457B2 (en) 2015-02-24 2018-08-27 Chimeric protein

Publications (1)

Publication Number Publication Date
WO2016135470A1 true WO2016135470A1 (en) 2016-09-01

Family

ID=52822149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2016/050451 WO2016135470A1 (en) 2015-02-24 2016-02-23 Chimeric protein

Country Status (21)

Country Link
US (3) US10098911B2 (ja)
EP (2) EP3197453B9 (ja)
JP (3) JP6836508B2 (ja)
KR (2) KR20230156817A (ja)
CN (2) CN116425882A (ja)
AU (1) AU2016225190B2 (ja)
BR (1) BR112017013689A2 (ja)
CA (1) CA2973107A1 (ja)
CL (1) CL2017002134A1 (ja)
DK (1) DK3197453T3 (ja)
ES (1) ES2930623T3 (ja)
GB (1) GB201503133D0 (ja)
HU (1) HUE060267T2 (ja)
IL (1) IL252840B (ja)
MX (1) MX2017007848A (ja)
PL (1) PL3197453T3 (ja)
PT (1) PT3197453T (ja)
RU (1) RU2746755C2 (ja)
SG (1) SG11201705300VA (ja)
WO (1) WO2016135470A1 (ja)
ZA (1) ZA201704231B (ja)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018068022A1 (en) * 2016-10-06 2018-04-12 Poseida Therapeutics, Inc. Inducible caspases and methods for use
WO2018224844A1 (en) 2017-06-09 2018-12-13 Autolus Limited Anti trbc1 antigen binding domains
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
GB201906126D0 (en) 2019-05-01 2019-06-12 Autolus Ltd Chimeric protein
CN110191955A (zh) * 2016-12-13 2019-08-30 西雅图儿童医院（Dba西雅图儿童研究所） 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
WO2019175209A1 (en) * 2018-03-14 2019-09-19 Medigene Immunotherapies Gmbh Inducible t cell receptors and uses thereof
WO2020035676A1 (en) 2018-08-13 2020-02-20 Autolus Limited Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ftl3
CN111164203A (zh) * 2017-08-02 2020-05-15 奥托路斯有限公司 表达嵌合抗原受体或工程化tcr并包含选择性表达的核苷酸序列的细胞
WO2020183131A1 (en) 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
WO2021048564A2 (en) 2019-09-13 2021-03-18 Autolus Limited Antigen-binding domain
WO2021123810A1 (en) 2019-12-20 2021-06-24 Autolus Limited Antigen-binding domain binding to psma
WO2022129910A1 (en) 2020-12-16 2022-06-23 Ucl Business Ltd Polypeptide
WO2022136874A1 (en) 2020-12-23 2022-06-30 Quell Therapeutics Limited Inducible signalling protein
US11643453B2 (en) 2017-10-12 2023-05-09 Autolus Limited Cell
WO2023099886A1 (en) 2021-11-30 2023-06-08 Quell Therapeutics Limited Signalling protein
US11851672B2 (en) 2017-10-25 2023-12-26 Autolus Limited CAR T-cells comprising transcriptional circuits
WO2024009093A1 (en) 2022-07-06 2024-01-11 Autolus Limited Engineered trispecific tancar expressing cells targeting cd33, cd123 and cll1 and uses thereof in cancer therapy
US11987804B2 (en) 2018-04-27 2024-05-21 Seattle Children's Hospital Rapamycin resistant cells

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201503133D0 (en) * 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
AU2018206485A1 (en) 2017-01-09 2019-07-11 Oisin Biotechnologies Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment
CN109593721B (zh) * 2017-09-30 2022-11-01 亘喜生物科技（上海）有限公司 具有自杀基因开关的靶向人间皮素的工程化免疫细胞
EP3703689A1 (en) * 2017-11-01 2020-09-09 Allogene Therapeutics, Inc. Modified caspase-9 polypeptides and methods of use thereof
GB201805918D0 (en) * 2018-04-10 2018-05-23 Autolus Ltd Cell
EP3784252A4 (en) 2018-04-18 2022-03-16 Oisin Biotechnologies, Inc. FUSOGENIC LIPID DNANOPARTICLES AND METHODS FOR THEIR PRODUCTION AND USE IN TARGET CELL SPECIFIC MANUFACTURE OF A THERAPEUTIC PROTEIN AND TREATMENT OF A TARGET CELL RELATED DISEASE, CONDITION OR DISORDER
CN112575035B (zh) * 2020-12-09 2022-11-29 贵州医科大学 一种诱导细胞凋亡的载体系统

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050425A2 (en) * 1998-03-30 1999-10-07 Baylor College Of Medicine Regulated apoptosis using chemically induced dimerization of apoptosis factors
US20040040047A1 (en) * 1998-03-30 2004-02-26 Spencer David M. Regulated apoptosis using chemically induced dimerization of apoptosis factors
US6916917B1 (en) * 1998-11-17 2005-07-12 California Institute Of Technology Chimeric pro-caspases and methods of using same
WO2012177927A1 (en) * 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2014197638A2 (en) * 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990022651A (ko) * 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
AU714904C (en) * 1995-06-07 2002-08-08 Ariad Pharmaceuticals, Inc. Rapamcycin-based regulation of biological events
AU2003226955A1 (en) 2002-04-19 2003-11-03 Bioimage A/S Translocation dependent complementation for drug screening
JP2008526889A (ja) * 2005-01-10 2008-07-24 リサーチ ディベロップメント ファウンデーション 癌治療のための標的化キメラ分子
KR101495651B1 (ko) * 2012-09-03 2015-03-03 한국과학기술원 빛에 의해 이합체 형성을 유도하는 융합단백질 및 그의 용도
CA2901115A1 (en) 2013-02-15 2014-08-21 The Regents Of The University Of California Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3114217A4 (en) 2014-03-07 2017-09-20 Bellicum Pharmaceuticals, Inc. Caspase polypeptides having modified activity and uses thereof
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
WO2016100236A2 (en) * 2014-12-15 2016-06-23 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
WO2016100241A2 (en) 2014-12-15 2016-06-23 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
GB201503133D0 (en) * 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
AU2020235395A1 (en) 2019-03-08 2021-09-02 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050425A2 (en) * 1998-03-30 1999-10-07 Baylor College Of Medicine Regulated apoptosis using chemically induced dimerization of apoptosis factors
US20040040047A1 (en) * 1998-03-30 2004-02-26 Spencer David M. Regulated apoptosis using chemically induced dimerization of apoptosis factors
US6916917B1 (en) * 1998-11-17 2005-07-12 California Institute Of Technology Chimeric pro-caspases and methods of using same
WO2012177927A1 (en) * 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2014197638A2 (en) * 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADRIAN FEGAN ET AL: "Chemically Controlled Protein Assembly: Techniques and Applications", CHEMICAL REVIEWS, vol. 110, no. 6, 9 June 2010 (2010-06-09), US, pages 3315 - 3336, XP055221903, ISSN: 0009-2665, DOI: 10.1021/cr8002888 *
DI STASI ET AL.: "Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy", NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, 2011, pages 1673 - 1683, XP002756622 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11718656B2 (en) 2016-10-06 2023-08-08 Poseida Therapeutics, Inc. Inducible caspases and methods for use
WO2018068022A1 (en) * 2016-10-06 2018-04-12 Poseida Therapeutics, Inc. Inducible caspases and methods for use
AU2017339511B2 (en) * 2016-10-06 2021-12-02 Poseida Therapeutics, Inc. Inducible caspases and methods for use
IL265664B1 (en) * 2016-10-06 2023-10-01 Poseida Therapeutics Inc Inducible caspases and methods of use
KR20190066616A (ko) * 2016-10-06 2019-06-13 포세이다 테라퓨틱스, 인크. 유도성 카스파제 및 사용 방법
US11377480B2 (en) 2016-10-06 2022-07-05 Poseida Therapeutics, Inc. Inducible caspases and methods for use
KR102447083B1 (ko) * 2016-10-06 2022-09-26 포세이다 테라퓨틱스, 인크. 유도성 카스파제 및 사용 방법
CN110267980A (zh) * 2016-10-06 2019-09-20 波赛达治疗公司 诱导型胱天蛋白酶及使用方法
RU2757058C2 (ru) * 2016-10-06 2021-10-11 Посейда Терапьютикс, Инк. Индуцируемые каспазы и способы использования
CN110191955A (zh) * 2016-12-13 2019-08-30 西雅图儿童医院（Dba西雅图儿童研究所） 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
CN110191955B (zh) * 2016-12-13 2024-05-31 西雅图儿童医院（Dba西雅图儿童研究所） 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
WO2018224844A1 (en) 2017-06-09 2018-12-13 Autolus Limited Anti trbc1 antigen binding domains
US11440961B2 (en) 2017-06-09 2022-09-13 Autolus Limited Anti TRBC1 antigen binding domains
US11434293B2 (en) 2017-06-09 2022-09-06 Autolus Limited Anti TRBC1 antigen binding domains
CN111164203A (zh) * 2017-08-02 2020-05-15 奥托路斯有限公司 表达嵌合抗原受体或工程化tcr并包含选择性表达的核苷酸序列的细胞
US11643453B2 (en) 2017-10-12 2023-05-09 Autolus Limited Cell
US11851672B2 (en) 2017-10-25 2023-12-26 Autolus Limited CAR T-cells comprising transcriptional circuits
JP2021515574A (ja) * 2018-03-14 2021-06-24 メディジーン イミュノテラピーズ ゲーエムベーハー 誘導性ｔ細胞レセプター及びその使用
JP7412006B2 (ja) 2018-03-14 2024-01-12 メディジーン イミュノテラピーズ ゲーエムベーハー 誘導性ｔ細胞レセプター及びその使用
WO2019175209A1 (en) * 2018-03-14 2019-09-19 Medigene Immunotherapies Gmbh Inducible t cell receptors and uses thereof
CN112119087A (zh) * 2018-03-14 2020-12-22 基因医疗免疫疗法有限责任公司 诱导型t细胞受体及其用途
US11987804B2 (en) 2018-04-27 2024-05-21 Seattle Children's Hospital Rapamycin resistant cells
WO2020035676A1 (en) 2018-08-13 2020-02-20 Autolus Limited Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ftl3
WO2020183131A1 (en) 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
WO2020222007A1 (en) 2019-05-01 2020-11-05 Autolus Limited Chimeric protein comprising a caspase 1 domain
GB201906126D0 (en) 2019-05-01 2019-06-12 Autolus Ltd Chimeric protein
WO2021048564A2 (en) 2019-09-13 2021-03-18 Autolus Limited Antigen-binding domain
WO2021123810A1 (en) 2019-12-20 2021-06-24 Autolus Limited Antigen-binding domain binding to psma
WO2022129910A1 (en) 2020-12-16 2022-06-23 Ucl Business Ltd Polypeptide
WO2022136874A1 (en) 2020-12-23 2022-06-30 Quell Therapeutics Limited Inducible signalling protein
WO2023099886A1 (en) 2021-11-30 2023-06-08 Quell Therapeutics Limited Signalling protein
WO2024009093A1 (en) 2022-07-06 2024-01-11 Autolus Limited Engineered trispecific tancar expressing cells targeting cd33, cd123 and cll1 and uses thereof in cancer therapy

Also Published As

Publication number Publication date
RU2017132293A3 (ja) 2019-06-19
IL252840A0 (en) 2017-08-31
JP2020078359A (ja) 2020-05-28
CA2973107A1 (en) 2016-09-01
KR102601849B1 (ko) 2023-11-14
US20170354682A1 (en) 2017-12-14
EP3197453B8 (en) 2022-09-28
US11103532B2 (en) 2021-08-31
IL252840B (en) 2021-03-25
US10098911B2 (en) 2018-10-16
JP2022111273A (ja) 2022-07-29
JP2018506975A (ja) 2018-03-15
CL2017002134A1 (es) 2018-03-16
PL3197453T3 (pl) 2023-02-27
CN107207621A (zh) 2017-09-26
KR20230156817A (ko) 2023-11-14
ZA201704231B (en) 2018-09-26
JP6836508B2 (ja) 2021-03-03
US20190015451A1 (en) 2019-01-17
AU2016225190A1 (en) 2017-07-27
EP4147696A1 (en) 2023-03-15
US20200222461A1 (en) 2020-07-16
CN107207621B (zh) 2023-04-18
EP3197453B1 (en) 2022-08-24
US10478457B2 (en) 2019-11-19
PT3197453T (pt) 2022-11-23
CN116425882A (zh) 2023-07-14
GB201503133D0 (en) 2015-04-08
EP3197453B9 (en) 2022-12-07
BR112017013689A2 (pt) 2018-03-06
DK3197453T3 (da) 2022-11-21
HUE060267T2 (hu) 2023-02-28
AU2016225190B2 (en) 2021-05-13
KR20170117555A (ko) 2017-10-23
SG11201705300VA (en) 2017-07-28
MX2017007848A (es) 2018-08-01
ES2930623T3 (es) 2022-12-20
RU2746755C2 (ru) 2021-04-20
EP3197453A1 (en) 2017-08-02
RU2017132293A (ru) 2019-03-25

Similar Documents

Publication Publication Date Title
US11103532B2 (en) Chimeric protein
KR20200088383A (ko) T-세포 수용체 및 베타 2-마이크로글로불린 발현을 제거하도록 유전자 변형된 불멸화 car-t 세포
CN112969784A (zh) 工程化调节性t细胞
CA3017213A1 (en) Genome edited immune effector cells
AU2016250200B2 (en) Chimeric protein
KR20220007675A (ko) 아세틸콜린 수용체 키메라 자가항체 수용체 세포의 조성물 및 방법
WO2020123933A1 (en) Dimerizing agent regulated immunoreceptor complexes
WO2020222007A1 (en) Chimeric protein comprising a caspase 1 domain
US11040094B2 (en) Compositions and methods for treating immunological dysfunction
CN117736301B (zh) 靶向巨细胞病毒pp65的TCR和表达其的T细胞及应用
CN117106061B (zh) 靶向巨细胞病毒抗原的tcr和表达其的t细胞及应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16707195

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2016707195

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15526097

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 252840

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/007848

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 11201705300V

Country of ref document: SG

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017013689

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2973107

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016225190

Country of ref document: AU

Date of ref document: 20160223

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017542093

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20177025985

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017132293

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112017013689

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170623